Scailyte quarterly update
Scailyte quarterly update April, highlighting the three high-profile strategic partnerships, securing long-term revenue and validating our business model. Prof. Woong-Yang Park Founder and CEO of Geninus. Here is his statement about our company – “Geninus aims to implement single-cell genome analysis techniques to facilitate personalised patient care. Scailyte’s machine learning model will add value to the single-cell gene expression profile of patients. Through collaboration with Scailyte, we hope to provide prognostic methods for immunotherapy response in precision medicine clinics.” Read more below:
Read our previous quarterly update here.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
Recent News
NextGen Omics Boston Conference
Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31
Recent News
Vijay Tiwari is appointed as Chair of the Scientific Advisory Board
Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board
Recent News
Endometriosis interview series
We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom
Recent News
Scailyte Announces a Collaboration with Turnstone Biologics
Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid
Recent News
BIO-Europe Spring 2023
We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica
Recent News
International Women's Day 2023
Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin
Recent News
Diana Stoycheva and Sarah Carl at Biomarkers 2023
We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i
Recent News
NextGen Omics Boston Conference
Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31
Vijay Tiwari is appointed as Chair of the Scientific Advisory Board
Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board
Recent News
Endometriosis interview series
We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom
Scailyte Announces a Collaboration with Turnstone Biologics
Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid
Recent News
BIO-Europe Spring 2023
We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica
Recent News
International Women's Day 2023
Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin
Diana Stoycheva and Sarah Carl at Biomarkers 2023
We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i